P171 Are the european society of cardiology pulmonary hypertension guideline risk assessment criteria associated with 12-month mortality?
BackgroundThe European Society of Cardiology (ESC) guidelines for management of pulmonary hypertension (PAH) advocate comprehensive assessment of patients to determine prognosis and to guide treatment decisions, using a set of risk assessment criteria based on expert advice. These criteria are coded...
Gespeichert in:
Veröffentlicht in: | Thorax 2017-12, Vol.72 (Suppl 3), p.A175 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | BackgroundThe European Society of Cardiology (ESC) guidelines for management of pulmonary hypertension (PAH) advocate comprehensive assessment of patients to determine prognosis and to guide treatment decisions, using a set of risk assessment criteria based on expert advice. These criteria are coded Red (high), Amber (medium) and Green (low). It is unclear whether these criteria are associated with short term survival.AimTo determine whether red/amber/green risk status according to ESC guidelines is associated with 12 month mortality.MethodsThis was a “snapshot” observational study using routinely collected clinical data for patients eligible for targeted drug treatment at a regional centre, under shared care with a national centre. All data available at the latest visit within the study period were collated, including demographics, echocardiogram and right heart catheterisation data. Data are reported as mean/median/count/%. Characteristics of deceased and surviving patients were compared using Mann-Witney U-test. Association with 12 month mortality was assessed using Receiver Operator Characteristics (ROC) curve analysis.ResultsRoutinely collected clinic data were available for 104 patients, echocardiograms for 88 and right heart catheter data for 68. 25% were male, mean age 68.2 years. 45.2% had connective tissue disease-associated PAH, 32.7% inoperable chronic thromboembolic PH, 18.3% Idiopathic PAH. 101 were on treatment, of which 35.6% were on monotherapy, 51.0% on dual oral therapy, 9.6% on intravenous treatments. Baseline data are shown in the table. 25% had one red criterion, 14.4% had two and 8.6% had three or more. 19 patients died in the 12 month follow-up period, 6 of whom had no red criteria. Deceased patients were older (p=0.015) and had shorter walking distance (p=0.003). Risk criteria were worse for symptom progression, WHO functional class, walking distance and for the overall number of red criteria. ROC-curve analysis showed that symptom progression (c-statistic 0.695, p=0.048), walking distance (0.748, p=0.012) and the overall number of red flags (0.710, p=0.033) were the only elements associated with 12 month mortality.Abstract P171 Table 1Median/%Red flags, n(%) Symptom progressionN/A11 (10.6)NT-proBNP (ng/L)60.52 (1.9)WHO functional classN/A13 (12.5)6 min walk distance (m)29528 (28)Echo RA area (cm2)17.5 5 (7.4)Right heart catheter (any criterion)N/A13 (19.1)ConclusionsThe ESC risk assessment criteria are associated with 12 month mor |
---|---|
ISSN: | 0040-6376 1468-3296 |
DOI: | 10.1136/thoraxjnl-2017-210983.313 |